Jazz Pharmaceuticals (JAZZ) Earnings Analysis
Jazz Pharmaceuticals (JAZZ) next reports earnings on 2026-08-03, consensus EPS 6.18 USD. Last quarter (2024-07-31) it beat with EPS 5.3 USD vs 4.68 USD est (+13.2%). It has beaten estimates in 1/1 recent quarters (100%). Trailing P/E 610.76.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does JAZZ next report earnings?
| Next earnings date | 2026-08-03 |
|---|---|
| Consensus EPS estimate | 6.18 USD |
| Revenue estimate | 1.11B |
JAZZ earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2024-07-31 | 5.3 USD | 4.68 USD | +13.2% | Beat |
Beat rate: 1/1 (100%) over reported quarters with consensus data.
JAZZ valuation and analyst view
| Trailing P/E | 610.76 |
|---|---|
| Trailing EPS | 0.47646 USD |
| Price / book | 3.42 |
| Dividend yield | 0.00% |
| Market cap | 15.83B |
| Analyst consensus | Buy (43 buy / 5 hold / 0 sell) |
| Avg price target | 262.5 USD |
Related research pages
Frequently asked questions
When is Jazz Pharmaceuticals (JAZZ)'s next earnings date?
Jazz Pharmaceuticals is next scheduled to report on 2026-08-03, with a consensus EPS estimate of 6.18 USD and revenue estimate of 1.11B.
Did JAZZ beat earnings last quarter?
In its 2024-07-31 report, JAZZ posted EPS of 5.3 USD versus a 4.68 USD estimate — a beat of 13.2%.
What is JAZZ's earnings track record?
Over the last 1 reported quarters with consensus data, JAZZ beat estimates 1 times (100%).
What is JAZZ's current P/E ratio and EPS?
JAZZ trades at a trailing P/E of 610.76 on trailing EPS of 0.4764620355411955 USD.
What do analysts rate JAZZ?
Analyst consensus is "Buy" across 48 ratings (0 strong buy, 43 buy, 5 hold, 0 sell, 0 strong sell). Average 12-month price target: 262.5 USD.